FAM172A

Across TCGA pan-cancer cohorts, FAM172A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated FAM172A data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FAM172A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FAM172A expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where FAM172A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.942	0.234	.001	45	view →
HNSC	DFS	Median	IV	0.527	0.787	.009	19	view →
CCRCC	DFS	Median	III,IV	0.818	0.244	.031	14	view →
LUAD	DFS	Quartile	III,IV	0.479	0.904	.006	13	view →
GBM	OS	Quartile	All	0.707	0.966	.023	1	view →
LSCC	OS	Median	All	0.800	1.000	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

FAM172A–PDAC (DFS)

Open the PDAC breakdown →